Establishment Labs Q1 revenue $59.9M (+44.7% YoY); raises FY guidance; adj. EBITDA positive for 3rd quarter

ESTABLISHMENT LABS HOLDINGS INC.

2026-Q1 EPS reported -$0.45 revenue$59,877,000

Revenue of $59.9M, up 44.7% YoY; US Motiva sales $19.6M (vs $6.2M Q1 2025).
Gross margin 70.7% (up from 67.2% YoY); operating loss narrowed to $6.5M from $16.9M.
Adjusted EBITDA of $1.2M vs loss of $12.1M YoY; cash balance $68.1M.
FY 2026 revenue guidance raised to $266.5M-$268.5M; minimally invasive revenue seen >$35M.
Expects free cash flow positive in H2 2026; reaffirms positive adjusted EBITDA each quarter.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ESTABLISHMENT LABS HOLDINGS INC. reported the first quarter ended March 31, 2026 results: revenue $59.9 million, net income $13.4 million. Guidance raised.

Period: the first quarter ended March 31, 2026
Revenue: $59.9 million
Net income: $13.4 million
Guidance: raised
Result: reported results

Exact text from the filing

breast aesthetics and reconstruction, today announced financial results for the first quarter ended March 31, 2026. First Quarter Highlights and Outlook (Unaudited) • Revenue of $59.9 million, up 44.7% from Q1 2025, with guidance raised to $266.5 million to $268.5 million • $19.6 million of Motiva sales in the United States, up 13.3% from Q4 2025 • Minimally invasive

View on SEC.gov

Browse all earnings releases →

ESTABLISHMENT LABS HOLDINGS INC. filing history →

Source: SEC EDGAR

accession 0001688757-26-000038

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.